DUPILUMAB

Dupilumab is a monoclonal antibody blocking IL4/IL13 signaling to treat atopic dermatitis and asthma. Side effects include conjunctivitis, injectionsite reactions, and mild rash. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 27fa26d1d219 Category: Tag:

Product Description


Mechanism of Action

Dupilumab is a fully human monoclonal antibody that blocks the IL4R subunit, inhibiting both IL4 and IL13 signalling. These cytokines drive type2 inflammation, epithelial barrier dysfunction and IgE class switching. Dupilumab disrupts STAT6mediated transcription and reduces eosinophilic inflammation.

Benefits and Advantages

Used in type2 immunity research, atopicdermatitis modelling, IL4/IL13 pathway studies, biologicmechanism analysis and epithelialinflammation assays.

Side Effects and Risks

Risks include conjunctivitis, injectionsite reactions, eosinophilia, herpes viral infections and rare hypersensitivity. Handle with monoclonalantibody precautions.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C6500H10176N1720O2024S42

Molecular Weight

147000.0 g/mol

CAS Number

1190268-29-6

Storage Condition

Store in a cool, dry place; protect from light

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

IUPAC/Chemical Name

Human monoclonal IgG4 antibody

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download